A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol

European Journal of Ophthalmology

Volumn 10, Issue 2, 2000, Pages 95-104

  Hedman, Katarina ^a,b   Alm, A ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b PFIZER INC   (United States)

Author keywords

Intraocular pressure; Latanoprost; Ocular hypertension; Open angle glaucoma; Prostaglandin; Timolol

Indexed keywords

LATANOPROST; TIMOLOL;

ARTICLE; CIRCADIAN RHYTHM; DATA ANALYSIS; DRUG EFFICACY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 0033917235     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210001000201     Document Type: Article

References (20)

1. Stjernschantz J, Resul B. Phenyl substituted prostaglandin analogs for glaucoma treatment. Drugs Future 1992; 8: 691-704.
2. Resul B, Stjernschantz J, No K, et al. Phenyl-substituted prostaglandins: potent and selective antiglaucoma agents. J Med Chem 1993; 36: 243-8.
3. Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 1995; 102: 1743-52.
4. Watson P, Stjernschantz J, the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996; 103: 126-37.
5. Camras CB, the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology 1996; 103: 138-47.
6. Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol 1996; 114: 929-32.
7. Alm A, Villumsen J. PhXA34 a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch Ophthalmol 1991; 109: 1564-8.
8. 2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993; 111: 1351-8.
9. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993; 100: 1297-304.
10. 2α. Arch Ophthalmol 1987; 105: 1112-6.
11. 2α increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 1989; 49: 389-402.
12. 2α 1-isopropylester in the cynomolgus monkey. Exp Eye Res 1989; 48: 707-16.
13. Ray WA, O'Day DM, Head S, Robinsson R. Statistical analysis for experimental models of ocular disease: continuous response measures. Curr Eye Res 1985; 5: 585-97.
14. Analysis of covariance. In: Snedecor GW, Cochran WG, ed. Statistical methods 7th edition. The Iowa State University Press, 1980; 365-88.
15. Regression and correlation. In: Colton T, ed. Statistics in medicine. Boston: Little Brown and Company, 1974; 189-217.
16. Blomqvist N. On the bias caused by regression toward the mean in studying the relation between change and initial value. J Clin Periodontol 1986; 13: 34-7.
17. Boger WP III, Puliafito CA, Steinert RF, Langston DP. Long-term experience with timolol ophthalmic solution in patients with open-angle glaucoma. Ophthalmology 1978; 85: 259-67.
18. Gandolfi SA. Restoring sensitivity to timolol after long-term drift in primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 1990; 31: 354-8.
19. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: Implications for uveoscleral outflow. Surv Ophthalmol 1997; 41 (suppl): S53-9.
20. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res 1998; 67: 179-91.